Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,204 across all filing types
Latest filing 2020-01-24 Capital/Financing Update
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Press Release
Capital/Financing Update Classification · 90% confidence The document is a press release announcing that Strides Pharma Science Limited has received tentative approval from the USFDA for a pharmaceutical product. It is a short communication focused on a specific event (product approval) and does not contain financial statements, management discussion, or detailed financial data. It is not an earnings release or a regulatory filing about financial results. It is also not a report publication announcement since it does not mention any report being attached or published. The content fits best under the category of Capital/Financing Update (CAP) as it relates to a significant business development impacting the company's product portfolio and market potential, which is typical for such announcements. Therefore, the appropriate classification is CAP with high confidence.
2020-01-24 English
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a short announcement informing stock exchanges about a scheduled Board Meeting to consider and approve unaudited financial results for a specific quarter and nine months period. It references Regulation 29(1) of SEBI Listing Regulations, which pertains to disclosure of Board Meetings. The document does not contain any financial data or results itself, but only announces the upcoming meeting. The length is only 1571 characters, indicating it is a brief notice rather than a full report. Therefore, it fits the category of Board/Management Information (MANG), which covers announcements of board meetings and related management information.
2020-01-23 English
Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding the publication of a newspaper advertisement about a National Company Law Tribunal (NCLT) convened meeting of equity shareholders. It references compliance with SEBI regulations and provides details about the meeting scheduled to consider and approve a Scheme of Amalgamation. The document is short (2156 characters) and primarily serves as a notification of the publication of a notice in newspapers. It does not contain financial data, detailed reports, or results of the meeting. Therefore, it is an announcement related to a meeting notice rather than the meeting materials or results themselves. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-01-20 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the successful closure of a USFDA inspection at the company's manufacturing site in Florida. It is dated January 20, 2020, and is addressed to stock exchanges with scrip codes mentioned, indicating a public announcement. The content focuses on operational and regulatory inspection outcomes rather than financial results, management changes, or detailed financial data. The document length is 4026 characters, which is relatively short and typical for a press release. There is no indication of it being a full financial report, audit report, or regulatory filing. It is not a report publication announcement since it does not mention any report being attached or published. The document fits best under a general regulatory announcement or compliance update category. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-01-20 English
Shareholders meeting
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice convening a meeting of equity shareholders as directed by the National Company Law Tribunal (NCLT) for the purpose of approving a Scheme of Amalgamation involving multiple companies. It includes the meeting date, venue, voting procedures, and extensive annexures such as the scheme itself, explanatory statements, supplementary accounting statements, board reports, and auditor certificates. The document is not a financial report but a formal notice and explanatory material related to a shareholder meeting to approve a merger/amalgamation scheme. This fits the category of Proxy Solicitation & Information Statement (PSI), as it provides information and requests votes for a meeting concerning a corporate restructuring transaction. The length and detail confirm it is the actual solicitation document, not just an announcement. Therefore, the appropriate classification is PSI with high confidence.
2020-01-17 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Strides Pharma Science Limited has received USFDA approval for a specific product, Loratadine OTC Softgel Capsules. It is a public announcement of a regulatory approval event, not a financial report, earnings release, or management discussion. The document is relatively short (4231 characters) and serves as a news update rather than a detailed report or filing. It does not contain financial statements, voting results, or management changes. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and press releases that do not fit other categories.
2020-01-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.